Prilenia, a clinical stage biotechnology company focused on the urgent mission to develop novel therapeutics to slow the progression of neurodegenerative diseases and neurodevelopmental disorders, has filed a European Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) for Lasīt vairāk...
I belong to the third generation of a family affected by Huntington’s Disease, but it wasn’t until 2024, thanks to the tireless efforts of my second father, F. Cook, that we were able to confirm how the disease entered the Lasīt vairāk...
Abu Dhabi, UAE; June 19, 2024: IROS, an Abu Dhabi-based contract research organization (part of the M42 group), has partnered with Prilenia Therapeutics, a clinical-stage biotech company, and the International Huntington’s Disease Association (IHA) to plan the first-ever clinical trial Lasīt vairāk...
“We are very pleased with these new data demonstrating a statistically significant, dose-dependent slowing of the progression of Huntington’s disease and lowering of NfL in the CSF at 24 months,” stated Walid Abi-Saab, M.D., chief medical officer of uniQure. “We believe Lasīt vairāk...
Today, Wave Life Sciences announced positive results from SELECT-HD, our Phase 1b/2a placebo-controlled trial evaluating the investigational therapy WVE-003. These results demonstrate that WVE-003 selectively lowers toxic, mutant huntingtin (mHTT) protein and preserves healthy, wild-type huntingtin (wtHTT) protein for individuals Lasīt vairāk...
At Month 12, mutant Huntingtin (mHTT) in the blood was lowered by 22% and 43% respectively for 5mg and 10mg doses. A similar result was seen in cerebrospinal fluid, where mHTT was lowered by 21% and 43% respectively, for 5mg Lasīt vairāk...
Earlier this week Sage Therapeutics announced the results of their SURVEYOR study which quantified the cognitive impact of Huntington’s Disease. Using the HD-Cognitive Assessment Battery (HD-CAB) they measured the difference between 29 healthy volunteers and 40 participants with HD. As Lasīt vairāk...
IHA prezidents Sveins Olafs Olafs Olsens pagājušajā mēnesī Abū Dabī notikušajā MENA reto slimību kongresā bija galvenais runātājs par Hantingtona slimību. Viņš runāja par to, ka reģionā steidzami ir jāizveido neirodeģeneratīvo slimību izcilības centrs, un Lasīt vairāk...
Šodien mēs esam ļoti laimīgi Hantingtonas kopienā. Uniqure paziņojums, ka uzņēmums ir saņēmis reģeneratīvās medicīnas progresīvās terapijas (RMAT) "apzīmējumu pētnieciskajai gēnu terapijai AMT-130 Hantingtona slimības gadījumā, ir vairāk nekā daudzsološs," saka prezidents. Lasīt vairāk...
Savās memuāros "Mēs eksistējam" Tanita Allena stāsta par grūtībām, ar kādām viņai nācās saskarties, lai pareizi diagnosticētu Hantingtona slimību. Atkal un atkal viņai tika uzstādīta nepareiza diagnoze, jo ārsti atteicās ņemt vērā, ka arī afroamerikāņi var pārmantot mutēto slimību. Lasīt vairāk...
Latvian 
English 
Arabic 
Bulgarian 
Chinese 
Czech 
Danish 
Dutch 
Estonian 
Finnish 
French 
German 
Greek 
Hungarian 
Indonesian 
Italian 
Japanese 
Lithuanian 
Polish 
Portuguese 
Romanian 
Russian 
Slovak 
Slovenian 
Spanish 
Swedish 
Turkish 
Ukrainian